LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

The trial will include patients with non-small cell lung, colorectal, head and neck, and cutaneous cancers with EGFR amplification.

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

Beyond analysts' top-and-bottom-line estimates for Merck (MRK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ...

As Merck gears up for its Q2 earnings, all eyes are on Keytruda, its oncology superstar. Keytruda, accounting for nearly half of Merck’s pharma sales, is anticipated to report Q2 sales of $7.90 ...

Merck’s MRK primary strength lies in oncology, propelled by its blockbuster PD-L1 inhibitor, Keytruda, which fuels robust ...

The startup is using elements of gene and cell therapy to create medicines that could be useful against an array of ...

Merck recently declared a Q4 dividend of $0.81 per share while also securing Health Canada's nod for KEYTRUDA® in cervical ...

Patients with rheumatoid arthritis who undergo immune checkpoint inhibition for metastatic non-small cell lung cancer demonstrate similar overall survival as those without RA, according to data ...

In June 2025, the FDA approved KEYTRUDA for perioperative use in adults with resectable, locally advanced head and neck ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Key Points Merck is seeking ways to prepare for a significant upcoming patent cliff.The company has just announced another acquisition that will help it achieve that goal.With its newer products, ...